GENERAL TOXIC PROPERTIES OF THE RADIOPHARMACEUTICAL 225AC-DOTA-PSMA

Radiopharmaceuticals, which are targeted prostate-specific membrane antigen (PSMA), are highly promising for radioligand therapy of prostate cancer. The aim of this work was to study the general toxic properties of radiopharmaceutical ²²⁵Ac-DOTA-PSMA after its single intravenous administration to animals (“acute” toxicity). It was shown that administration of ²²⁵Ac-DOTA-PSMA to mice and rats (male and female) at doses 100, 200 and 500 kBq/kg was adequately undergone by the animals. No significant signs of intoxication or animal death were observed. No pathomorphological changes of organs and tissues were revealed at autopsy of animals. In mice treated with ²²⁵Ac-DOTA-PSMA at doses of 200 and 500 kBq/kg a decrease of salivary gland weight by 8–15% was observed when compared with the control group (p > 0.05).

1. Prostate cancer. Clinical recommendations. https://oncology-association.ru/wp-content/uploads/2021/02/rpzh.pdf (Accessed 02.04.2024).

2. Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) // Состояние онкологической помощи населению России в 2022 году. 2022. Москва: МНИОИ им. П.А. Герцена.

3. Тищенко В.К., Петриев В.М., Власова О.П. и др. // Ядерн. физ. инжинир. 2022. Т. 13 (6). С. 611 [ Tishchenko V.K., Petriev V.M., Vlasova O.P., et al. // Phys. At. Nucl. 2022. V. 85 (9). P. 1608–1612].

4. Yadav M.P., Ballal S., Sahoo R.K., et al. // Am. J. Roentgenol. 2019. V. 213. P. 275–285.

5. Ahmadzadehfar H., Rahbar K., Baum R.P., et al. // Eur. J. Nucl. Med. Mol. Imaging. 2021. V. 48. P. 113–122.

6. Hofman M.S., Violet J., Hicks R.J., et al. // Lancet Oncol. 2018. V. 19. P. 825–833.

7. Keam S.J. // Mol. Diagn. Ther. 2022. V. 26 (4). P. 467–475.

8. Крылов В.В., Легкодимова Н.С., Кочетова Т.Ю. и др. // Лучевая диагностика и терапия. 2022. № 4 (13). С. 75–85.

9. Гелиашвили Т.М., Крылов А.С., Блиганов П.И. и др. // Онкологический журнал: лучевая диагностика, лучевая терапия. 2023. Т. 6 (1). С. 88–96.

10. Selcuk N.A., Beydagi G., Demirci E., et al. // J. Nucl. Med. 2023. V. 64. P. 1574–1580.

11. Ferrier M.G., Radchenko V. // J. Med. Imaging Radiat. Sci. 2019. V. 50. P. S58–S65.

12. Juzeniene A., Stenberg V.Y., Bruland O.S., et al. // Cancers. 2021. V. 13. P. 779.

13. Kratochwil C., Bruchertseifer F., Rathke H., et al. // J. Nucl. Med. 2018. V. 59 (5). P. 795–802.

14. Sathekge M., Bruchertseifer F., Vorster M., et al. // J. Nucl. Med. 2020. V. 61 (1). P. 62–69.

15. Zacherl M.J., Gildehaus F.J., Mittlmeier L., et al. // J. Nucl. Med. 2021. V. 62. P. 669–674.

16. Lawal I.O., Morgenstern A., Vorster M., et al. // Eur. J. Nucl. Med. Mol. Imaging. 2022. V. 49 (10). P. 3581–3592.

17. Kratochwil C., Bruchertseifer F., Rathke H., et al. // J. Nucl. Med. 2017. V. 58 (10). P. 1624–1631.

18. Satapathy S., Sood A., Das C.K., et al. // Prostate Cancer Prostatic Dis. 2021. V. 24. P. 880–890.

19. Kratochwil C., Bruchertseifer F., Giesel F.L., et al. // J. Nucl. Med. 2016. V. 57. P. 1941–1944.

20. Методические рекомендации по использованию лабораторных животных для сотрудников ФГБУ “НМИЦ радиологии” МЗ РФ, участвующих в доклинических исследованиях. 2020. Москва: НМИЦ радиологии.

21. European Convention for the Protection of Vertebrate Animals, Which Are Used for Experimental or Other Scientific Purposes. 2024. https://rm.coe.int/168007a6a8.

22. Heynickx N., Herrmann K., Vermulen K., et al. // Nucl. Med. Biol. 2021. V. 98–99. P. 30–39.

23. Roy J., Warner B.M., Basuli F., et al. // Cancer Biother. Radiopharm. 2020. V. 35 (4). P. 284–291.

24. Yadav M.P., Ballal S., Sahoo R.K., et al. // Theranostics. 2020. V. 10. P. 9364–9377.